Candriam S.C.A. Exelixis, Inc. Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Exelixis, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 548,119 shares of EXEL stock, worth $18.5 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

548,119

Previous 707,635 22.54%

Holding current value

$18.5 Million

Previous $15.9 Million 10.55%

% of portfolio

0.08%

Previous 0.1%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$21.96 - $27.6 $3.5 Million - $4.4 Million	-159,516 Reduced 22.54%	548,119 $14.2 Million
Q2 2024 Aug 05, 2024	SELL	$20.34 - $23.73 $973,106 - $1.14 Million	-47,842 Reduced 6.33%	707,635 $15.9 Million
Q1 2024 May 03, 2024	BUY	$20.17 - $23.93 $884,494 - $1.05 Million	43,852 Added 6.16%	755,477 $17.9 Million
Q3 2023 Nov 13, 2023	SELL	$19.04 - $22.74 $5.52 Million - $6.59 Million	-290,012 Reduced 28.95%	711,625 $15.5 Million
Q2 2023 Aug 08, 2023	SELL	$18.17 - $20.48 $9.73 Million - $11 Million	-535,284 Reduced 34.83%	1,001,637 $19.1 Million
Q1 2023 May 12, 2023	SELL	$16.3 - $19.41 $11.5 Million - $13.7 Million	-706,117 Reduced 31.48%	1,536,921 $29.8 Million
Q4 2022 Feb 13, 2023	BUY	$14.96 - $17.39 $2.57 Million - $2.99 Million	172,085 Added 8.31%	2,243,038 $36 Million
Q3 2022 Nov 10, 2022	BUY	$15.68 - $22.27 $2.59 Million - $3.68 Million	165,409 Added 8.68%	2,070,953 $32.5 Million
Q2 2022 Aug 03, 2022	BUY	$17.44 - $23.16 $5.64 Million - $7.49 Million	323,228 Added 20.43%	1,905,544 $39.7 Million
Q1 2022 May 13, 2022	SELL	$17.03 - $22.67 $18.3 Million - $24.4 Million	-1,075,498 Reduced 40.47%	1,582,316 $35.9 Million
Q4 2021 Feb 10, 2022	SELL	$15.84 - $21.88 $1.28 Million - $1.77 Million	-80,989 Reduced 2.96%	2,657,814 $54.3 Million
Q3 2021 Nov 09, 2021	SELL	$16.3 - $21.14 $475,047 - $616,104	-29,144 Reduced 1.05%	2,738,803 $57.9 Million
Q2 2021 Jul 20, 2021	BUY	$17.95 - $25.56 $8.23 Million - $11.7 Million	458,568 Added 19.86%	2,767,947 $50.4 Million
Q1 2021 Apr 29, 2021	BUY	$20.53 - $25.22 $677 - $832	33 Added 0.0%	2,309,379 $44.5 Million
Q4 2020 Jan 22, 2021	BUY	$18.39 - $24.8 $19.9 Million - $26.9 Million	1,084,095 Added 88.48%	2,309,346 $46.4 Million
Q3 2020 Oct 19, 2020	BUY	$20.67 - $26.94 $17.2 Million - $22.5 Million	833,965 Added 213.13%	1,225,251 $30 Million
Q2 2020 Jul 23, 2020	SELL	$16.46 - $27.42 $4.4 Million - $7.33 Million	-267,230 Reduced 40.58%	391,286 $9.29 Million
Q1 2020 May 26, 2020	BUY	$14.46 - $21.8 $650 - $981	45 Added 0.01%	658,516 $11.3 Million
Q4 2019 Jan 21, 2020	SELL	$15.15 - $18.89 $361,645 - $450,923	-23,871 Reduced 3.5%	658,471 $12,000
Q3 2019 Oct 21, 2019	SELL	$17.68 - $22.65 $972,400 - $1.25 Million	-55,000 Reduced 7.46%	682,342 $12,000
Q2 2019 Aug 01, 2019	BUY	$18.93 - $24.75 $458,106 - $598,950	24,200 Added 3.39%	737,342 $15.7 Million
Q1 2019 May 02, 2019	BUY	$19.6 - $24.76 $3.24 Million - $4.09 Million	165,182 Added 30.14%	713,142 $17 Million
Q4 2018 Feb 14, 2019	BUY	$13.65 - $21.8 $2.53 Million - $4.04 Million	185,460 Added 51.16%	547,960 $10.8 Million
Q3 2018 Nov 07, 2018	BUY	$15.87 - $22.4 $1.63 Million - $2.31 Million	103,000 Added 39.69%	362,500 $6.42 Million
Q2 2018 Aug 14, 2018	BUY	$18.56 - $22.45 $668,160 - $808,200	36,000 Added 16.11%	259,500 $5.59 Million
Q1 2018 May 09, 2018	BUY	$22.15 - $31.89 $1.09 Million - $1.56 Million	49,000 Added 28.08%	223,500 $4.95 Million
Q4 2017 Feb 07, 2018	SELL	$24.23 - $30.93 $666,325 - $850,575	-27,500 Reduced 13.61%	174,500 $5.31 Million
Q3 2017 Nov 03, 2017	BUY	$23.35 - $29.24 $4.72 Million - $5.91 Million	202,000	202,000 $4.89 Million

Others Institutions Holding EXEL

# of Institutions

502

Shares Held

243M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account